Mercredi 6 novembre 2019 – 17h00
FER Genève – 98, rue de Saint Jean – 1201 Genève
L’association Genève Sciences de la Vie a le plaisir de vous convier à fêter ses 70 ans pour une soirée de réflexion sur le passé, le présent et le futur des sciences de la vie.
Avec la participation de:
Pierre Maudet, Conseiller d’État.
Luc Ferry, écrivain et philosophe.
Geneviève Berger, médecin et biophysicienne,
Directrice du département R&D du groupe Firmenich.
Table ronde animée par Benoît Dubuis.
News
Please find below the last exciting news from GSV & Life Sciences Sector.FDA officially authorizes its first serological antibody blood test for COVID-19
The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19, developed by Cellex, allowing people to gauge a person’s immune response to the novel coronavirus.
More info
GSK allies with Innovax for COVID-19 vaccine R&D project
GlaxoSmithKline has teamed up with Xiamen Innovax Biotech to evaluate a vaccine against the novel coronavirus behind the COVID-19 pandemic. The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.
More info
J&J inks Fate deal to move into allogeneic CAR therapies
Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies. The deal, which features $3 billion in milestones, tasks Fate with using its induced pluripotent stem cell (iPSC) platform to develop drugs based on four targets picked out by J&J.
More info
Horizon snaps up Curzion Pharma and its ex-Sanofi rare disease drug
Horizon Therapeutics has added to its growing acquisitive pipeline with the buyout of Curzion Pharmaceuticals for just $45 million.
More info
BioNTech, CureVac tell regulators to lower clinical trial bar if they want a COVID-19 vaccine quickly
Two German biotech companies at the start of a race to create new vaccines against the COVID-19 pandemic are warning the EMA and FDA they will need traditional clinical trial hurdles removed if governments want the inoculations as quickly as possible.
More info
Zentalis pulls off speedy $165M IPO amid pandemic-driven uncertainty
The new coronavirus has injected all kinds of uncertainty into the biotech world, leading companies to delay clinical trials, reorganize their pipelines and hold off on their IPOs. Not so for Zentalis Pharmaceuticals, which priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.
More info
COVID-19 vaccine packed into skin patch shows promise in mice
Researchers at the University of Pittsburgh School of Medicine developed a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity and that can be delivered into the skin with a Band-Aid-like patch. They're planning to apply to the FDA for approval to start clinical trials soon.
More info
Business Continuity Resource : Nous avons encore besoin de vous
La bataille économique provoquée par la pandémie de COVD-19 est loin d’être terminée avec de...
More info
[Campus Biotech] accueille une étude de séroprévalence pour la population genevoise
Mesurer dès aujourd’hui le taux de pénétration du SARS-CoV-2 dans une population donnée est une...
More info
[UniverCité] Made@UC imprime des visières de protection pour les EMS de Renens
La force d’une communauté se ressent pleinement lorsqu’elle s’adonne à un effort commun. En réponse...
More info
[Infographics] …ET ON (S’)EN SORT COMMENT?
Nous sommes en semi-confinement depuis un peu plus de deux semaines. Vous commencez à trouver...
More info
[ETUDE CLINIQUE] COVISTRESS : Et vous, comment vous sentez-vous ?!
Nous avons besoin de vous ! Offrez quelques minutes à la recherche en participant à l’étude...
More info
Arch raises $1.5B to back early-stage biotechs through accelerating 'healthcare revolution'
Arch Venture Partners has raised $1.5 billion to place another round of bets on early-stage biotechs. The VC shop, which lists Alnylam and Juno among its previous investments, raised the money across two funds that will deploy cash to help biotechs get started and grow into more established players.
More info
Gilead's Kite taps Teneobio to build next-gen CAR-Ts for multiple myeloma
Although front-line treatments for multiple myeloma work well for most patients, many of them eventually relapse, running out of drugs to treat their cancer. Gilead Sciences’ Kite Pharma is working on new CAR-T therapies for these patients—and it’s enlisted Teneobio’s antibody technology to do so.
More info
Giuliani-promoted COVID-19 therapy from Celularity nabs FDA speedy trial start
A new and unproved COVID-19 cell therapy from a New Jersey biotech has been given a quick trial approval by the FDA, coming just days after President Donald Trump’s personal attorney and former New York City Mayor Rudy Giuliani pushed for the med to be trialed ASAP.
More info
EuroBiotech: More Articles of Note
In our EuroBiotech roundup this week, AM-Pharma raises €23 million, Nordic Nanovector makes cuts and Neurimmune, Ethris plan COVID-19 trial.
More info
Amgen teams up with Adaptive to both treat and prevent COVID-19
After The Wall Street Journal first broke the news this week, Amgen and new partner Adaptive Biotechnologies have confirmed they are the latest pharma-biotech duo joining forces against the pandemic.
More info
EuroBiotech Report—Lilly-Sitryx, Genfit and COVID-19, Gilead tests remdesivir in U.K. and more
In this week's EuroBiotech Report, Sitryx inks Lilly deal, Genfit downplays COVID-19 impact on NASH data and Gilead tests remdesivir in U.K.
More info
Chutes & Ladders—Kewalramani officially takes over as Vertex CEO
Vertex moves Kewalramani into CEO post; Pfizer taps Gates Foundation head to board; Sera taps Moyes as CFO.
More info
Companies roll out remote COVID-19 monitoring tools to free up hospital space
Late last month, the FDA began giving developers of remote patient monitoring devices some extra leeway when it comes to making marketing claims, allowing them to pitch their use to hospitals responding to the COVID-19 crisis.
More info
VenBio Partners raises $394M fund 'to turn great science into impactful medicine'
The COVID-19 pandemic may be disrupting clinical trials and drug launches, but it’s not holding up venture firms intent on bankrolling innovative biotech startups. With Arch Venture Partners, Flagship Pioneering and now venBio unveiling their latest efforts, it looks like everyone’s raising a life sciences fund this week.
More info
BD to offer fingerstick antibody blood test for COVID-19
BD will begin offering a point-of-care COVID-19 antibody assay, which operates like a combination of a blood glucose test and a home pregnancy test.
More info
Compass Therapeutics' immuno-oncology prospect clears solid tumors in mice
The expression of CD137 on immune cells has made the protein receptor an attractive target in the development of new cancer immunotherapy drugs. Now, Compass Therapeutics has preclinical data showing that its CD137 agonist, CTX-471, could work safely in solid tumors, and it's advancing the drug into phase 1 human trials.
More info
FDA creates program to speed up coronavirus therapies
The FDA has created an emergency program to accelerate the development of treatments for the novel coronavirus. By redeploying staff, the FDA thinks it can respond to COVID-19-related requests and review protocols within 24 hours of receipt.
More info
As U.K.'s coronavirus toll surges, Gilead kick-starts remdesivir trials across the country
With Prime Minister Boris Johnson infected and isolated in Downing Street, and other top officials similarly afflicted with COVID-19, the U.K. is joining in the testing for Gilead Sciences' much-hyped antiviral candidate remdesivir. The trial news comes as case counts surge and officials hustle to get hospitals ready for a surge in patients.
More info
Microsoft lends petaflops to ImmunityBio’s coronavirus protein modeling efforts
NantWorks’ ImmunityBio has begun a supercomputing collaboration with Microsoft to map out the spike protein of the novel coronavirus—the means it uses to pry its way into and infect human cells.
More info
Smith+Nephew set to mass produce new ventilator from Oxford, King's College London
Smith+Nephew is contracting with the U.K. government to build a new ventilator specifically designed for the large-scale production needed to combat the spread of COVID-19.
More info
Flagship raises $1.1B to create biotechs for post-pandemic world
Flagship Pioneering has raised a $1.1 billion fund to create another batch of biotechs. The timing of the fund has Flagship peering into an uncertain future, trying to discern what opportunities will be attractive and impactful in the world that emerges from the COVID-19 pandemic.
More info
With Bristol Myers' latest CAR-T filing, Celgene investors inch closer to payout
Bristol Myers Squibb and bluebird bio filed their BCMA-targeting CAR-T therapy for FDA approval, teeing it up for a potential green light in 2020—and laying the groundwork for a potential payout to Celgene investors. The treatment, known as bb2121 or idecabtagene vicleucel (ide-cel), is one of three programs upon which BMS’ acquisition of Celgene hinged.
More info
iTeos reels in $125M to shepherd I-O prospects through the clinic
Nearly two years after raising $75 million to move two immuno-oncology meds into the clinic, iTeos Therapeutics has come back for more. Now, it’s picking up $125 million in a series B2 round that will push its lead assets through phase 1/2 trials.
More info
[Infographics] Pyramide de la désinformation
Une analyse sans nuance nous ferait conclure que plus une information est virale, moins elle...
More info
Coronavirus: SOS entreprises! Les entrepreneurs aident les entrepreneurs
Face au coronavirus, les mesures prises par les autorités sont nécessaires et drastiques. Mais certaines...
More info
Un confinement complet coûterait près de 29 milliards par mois
Un confinement complet de la population en Suisse, comme cela est notamment le cas en...
More info
Sécurité : Swisscom va détecter les attroupements via les mobiles
Sur une demande de la Confédération, Swisscom va détecter les attroupements via les téléphones mobiles....
More info
Télémédecine: une révolution enfin en marche
Partout en Suisse romande, des centaines de médecins adoptent la téléconsultation ces jours-ci pour des...
More info